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ABSTRACT 
Objective: Type 2 diabetes mellitus has been linked with cognitive decrement and an increased risk 
of dementia in older people. Less is known about whether diabetes affects cognition at younger ages. 
The objective of this meta-analysis was to examine possible differences (effect sizes) in cognitive 
performance between middle-aged type 2 diabetic patients and healthy controls. Secondary aim was 
to examine whether age is related to the magnitude of effect sizes.   
Method: Electronic databases and lists of references of selected articles were used to search for 
studies examining type 2 diabetes and cognition in patients under age 65 compared to healthy 
controls. Twelve studies met the inclusion criteria. Standardized mean differences (Hedges’s g) were 
calculated for main cognitive domains and their subdomains. Association between age and effect 
sizes was evaluated with meta-regression analyses. Publication bias and methodological quality of 
the studies were assessed.  
Results: Patients performed worse than controls in several cognitive functions. The largest 
differences were found in information processing speed (g=-0.68), attention/concentration (g=-0.55), 
executive functions (g=-0.51), and working memory (g=-0.51). There was no significance difference 
in visual memory (g=-0.15). Age was significantly related to the effect size in information processing 
speed, language, and verbal memory and visual memory. However, the direction of association varied 
across these cognitive domains. 
Conclusions: The results suggest that cognitive decrement in diabetes is not restricted to older people, 
but may begin to appear in middle age. More attention should be paid to early recognition and 
treatment of diabetes-related cognitive decrement in health care systems. 
Keywords: Attention; Cognition; Diabetes Mellitus, Type 2; Executive Function; Memory; Middle 
Aged; Neuropsychology 
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INTRODUCTION 
 
Type 2 diabetes is a growing global health problem with great socio-economic impact. It is a 
heterogeneous metabolic disease characterized by elevated blood glucose levels caused by insulin 
resistance and inadequate insulin production (American Diabetes Association, 2017). In 2015, a total 
of some 415 million people lived with diabetes, and most of them had type 2 diabetes (International 
Diabetes Federation, 2015). The association between type 2 diabetes and cognitive impairment and 
dementia in older people is now widely acknowledged (Biessels, Staekenborg, Brunner, Brayne, & 
Scheltens, 2006; Cheng, Huang, Deng, & Wang, 2012), but whether diabetes affects cognitive 
functions already in middle age remains less clear. For example, most research on diabetes-related 
cognitive dysfunction has focused on people over age 65. However, as the prevalence of diabetes is 
growing in younger age groups (International Diabetes Federation, 2015), there is reason to expect 
that cognitive symptoms will also begin to increase in middle-aged and younger people. Early 
detection of cognitive symptoms could help to improve patients’ quality of life and the management 
of diabetes, as the treatment of diabetes is mostly dependent on the patient and requires many 
cognitive abilities such as memory and executive functions (Tomlin & Sinclair, 2016). Good glycemic 
control in midlife could in turn help to prevent late-life cognitive decline (Tuligenga et al., 2014). 
There is thus an obvious need for more information about the possible early adverse effects of diabetes 
on cognitive functions.   
Numerous reviews and meta-analyses link type 2 diabetes to cognitive deficits and describe 
the multiple mechanisms underlying those deficits in older people (Awad, Gagnon, & Messier, 2004; 
Kodl & Seaquist, 2008; McGrimmon, Ryan, & Frier, 2012; Monette, Baird, & Jackson, 2014; Palta, 
Schneider, Biessels, Touradji, & Hill-Briggs, 2014; Reijmer, van den Berg, Ruis, Kappelle, & 
Biessels, 2010; Sadanand, Balachandar, & Bharath, 2015; Vincent & Hall, 2015). According to these 
studies, cognitive deficits in diabetes patients are most frequently evident in the domains of memory, 
executive functions and speed of information processing. In contrast, it seems that visuospatial 
functions and language processes are relatively unaffected. For example, Reijmer et al. (2010)  
conclude that patients with diabetes show worse performance than controls especially in processing 
speed, verbal memory, attention and executive functions, with effect sizes ranging from -0.2 to -0.8. 
They discuss the numerous diabetes-specific and comorbid risk factors associated with cognitive 
decrement, such as hypo- and hyperglycemia, microvascular complications, hypertension, 
depression, and stroke. Furthermore, Reijmer et al. (2010) point out that even though cognitive 
decrement may progress slowly over time, it can already begin to appear in the pre-diabetic stages, 
with the presence of hyperinsulinemia and impaired glucose metabolism. Despite these findings and 
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the numerous reviews and studies conducted in older patients with diabetes, no review or meta-
analysis exists that focuses specifically on the middle-aged.  
In order to increase awareness and improve the treatment of early cognitive decrement 
associated with diabetes, this meta-analysis aims to give insight into the relationship between type 2 
diabetes and cognitive functions in people aged 65 or younger. Specifically, the objective was to 
determine the possible differences (effect sizes) between middle-aged patients with type 2 diabetes 
and healthy controls in the most common cognitive domains. Secondary aim was to examine whether 
the magnitude of effect sizes is related to the age of diabetic patients.   
 
METHODS 
 
This meta-analysis was conducted in accordance with Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) standards (Moher, Liberati, Tetzlaff, & Altman, 2009). 
 
Selection of studies 
Articles published between January 2000 and January 2017 were searched from the following 
electronic databases: PubMed/MEDLINE, Science Direct, Wiley Online Library, Web of Science, 
Scopus, Ovid, PsycARTICLES, PsycINFO, CINAHL, and Academic Search Premier. The search 
was conducted in January 2017. The choice of timeframe was based on advances made in 
neuropsychological methods from 2000 onwards. The following cognitive function search terms were 
used: “cognition”, “cognitive function”, “neuropsychological”, “mental”, “intelligence”, “executive 
function”, “memory”, “processing speed”, “psychomotor speed”, “attention”, “verbal”, “visual”, 
“visuospatial”, “learning”, and “fluency”. These words were combined with the following type 2 
diabetes-related search terms: “type 2/II diabetes”, “type 2/II diabetic”, and “diabetes mellitus 2/II”. 
The search terms were restricted to the title of the article. When possible, searches were limited to 
articles in English, articles with abstracts, and peer-reviewed journal articles. Lists of reference in the 
selected articles were also scanned for possible additional studies.  
The search results were screened by researchers based on titles, abstracts and full texts. 
Disagreements were resolved by consensus. The exclusion criteria were as follows: 1) article not 
available in English, 2) pharmacological study, 3) intervention study, 4) animal study, 5) case study, 
6) letter, comment, opinion, poster, or only abstract available, 7) study focused on the effects of acute 
hypo- or hyperglycemia, 8) psychometric study (e.g. purely standardization study), 9) cognitive 
functions not in focus of the study (e. g. study focused only on 
neurophysiological/neuroanatomical/neurobiological functioning in diabetes), 10) study covered 
only mild cognitive impairment or dementia, 11) cognitive functions not assessed with a standard 
  Pelimanni-Diabetes and Cognition 
5 
neuropsychological method, 12) review or meta-analysis, 13) age of diabetic patients over 65 based 
on mean and standard deviation (SD), or age not available, 14) no healthy control group, and 15) data 
not available to calculate effect sizes. Duplicates were also excluded.  
 
Data extraction and management 
One author (E. Pelimanni) independently extracted the following data from the studies: author(s), 
year of publication, sample sizes and demographic data including age, education and gender 
distribution of patient and control group, study design and sampling method, diabetes-related factors 
including glycated hemoglobin (HbA1c) and duration of the disease, and neuropsychological 
methods used. Mean scores and SDs for the groups in neuropsychological tests were also extracted 
for effect size calculations. If a study reported standard errors of the mean (SEMs) instead of SDs, 
those were converted into SDs. For purposes of assessing the quality of the studies, additional 
information was extracted regarding the assessment of diabetes status, participant eligibility criteria 
and selection methods, confounding factors controlled for, and whether studies had used blind 
assessment of cognitive functions. Three studies did not report the mean or SD of the age of the 
diabetic group, and nine had missing neuropsychological data for the effect size calculations. The 
authors of these studies were contacted via e-mail to request the relevant information. 
To evaluate the effects of diabetes on cognitive functions, neuropsychological tests were 
assigned to one of the following cognitive domains and subdomains according to Lezak, Howieson, 
Bigler, and Tranel (2012) and Gurd, Kischka, and Marshall (2012): information processing speed 
(including psychomotor speed and motor speed), attention/concentration, working memory, 
executive functions (including verbal fluency and others), verbal memory (immediate and delayed), 
visual memory (immediate and delayed), language, and perception/construction (Supplement 1). The 
executive functions (others) category included methods evaluating functions such as inhibition, 
mental flexibility, planning, and abstract reasoning. Tests that could not be classified were not 
included in the analyses. If a study included multiple publications based on the same participants, the 
neuropsychological data were used only once and the most detailed article was included. In case a 
study had compared more than two groups, only data for the diabetic and healthy control group were 
extracted. In longitudinal studies, only baseline data were used in order to prevent the bias with using 
the same population twice in the same cognitive measurements. 
 
Statistical analyses and assessment of risk of bias 
To determine the magnitude of cognitive performance difference between patient and control group, 
standardized mean difference (SMD) effect sizes and their 95% confidence intervals (CIs) were 
calculated for cognitive domains and subdomains. Effect sizes were also calculated for individual 
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tests because the same cognitive tests were grouped together in the meta-analysis for cognitive 
domains and subdomains. SMDs were calculated as Hedges’s g by dividing the mean group 
difference in scores by pooled weighted SDs among participants (Borenstein, Hedges, Higgins, & 
Rothstein, 2009). Hedges’s g was selected because it is an unbiased estimator and corrects the upward 
bias in effect size in case of small sample sizes. Random effects models were used in all analyses due 
to the expected variability between study populations from sources other than sampling error; fixed 
effects models were therefore not appropriate (Field & Gillett, 2010). A negative effect size indicates 
that patients performed worse than controls. The presence of true heterogeneity in effect sizes was 
assessed with Cochran’s Q, and a p-value of 0.10 was used to indicate statistical significance due to 
the reported low power of the test (Hardy & Thompson, 1998). Heterogeneity was also quantified 
with I2, which represents the percentage of total variation in effect sizes that is caused by 
heterogeneity rather than chance (Higgins, Thompson, Deeks, & Altman, 2003). The association 
between age and effect sizes was examined with meta-regression analyses. Random-effect meta-
regression analyses were performed to all main cognitive domains and the mean ages of the patient 
groups were used as a moderator variable. Analyses were conducted using individual effect sizes 
from the studies as meta-regression was not possible for data in which single outcomes were grouped 
into categories. All data were analysed using Comprehensive Meta-Analysis (CMA) software version 
3 (Borenstein, Hedges, Higgins, & Rothstein, 2014). 
Publication bias or the presence of small study effects was assessed by examining funnel plots 
from the main cognitive domains with individual effect sizes from studies on the X-axis and inversed 
standard errors (SEs) on the Y-axis. Smaller studies appear at the bottom of the graph and because of 
higher SE, their effect estimates tend to show more variation. In contrast, larger studies appear at the 
top of the graph and because of less SE, they are usually more closely clustered around the mean 
effect size. In the absence of publication bias the graph will resemble a funnel, but in the presence of 
publication bias it will be asymmetric. This is because small studies with non-significant results are 
less likely to be published than large studies, and thus there will be more plots to the left bottom of 
the graph than to the right (Borenstein et al., 2009). Planned analyses of trim-and-fill, which shows 
adjusted effect size after taking account of possible publication bias (Duval & Tweedie, 2000), were 
not conducted since many studies included multiple different assessment methods within the same 
cognitive domain, and analyses were not possible for data in which single outcomes were grouped 
into categories. Instead, funnel plot asymmetry was evaluated subjectively, and if significant outliers 
were detected, sensitivity analyses were made by repeating the effect size calculation after removing 
the outliers.  
In addition to publication bias, risk of bias was evaluated at the study level by assessing the 
methodological quality of the studies. There is currently no consensus on the best method for 
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assessing the methodological quality of the non-randomized studies in meta-analyses. This 
assessment was here done using the Newcastle-Ottawa Quality Assessment Scale for non-randomized 
studies (Stang, 2010; Wells et al., 2014), with modifications based on Cochrane Collaboration’s 
recommendations in order to meet the specific requirements of this meta-analysis (Higgins & Green, 
2011). Factors evaluated included the adequate definition and representativeness of patients and 
controls, control for confounding effects of age and education, and blind assessment of cognitive 
functions. Adequate definition of patients means that the presence of diabetes was confirmed by 
medical examination, from medical records, or based on the use of antidiabetic medication and not 
based on self-report. Patients were considered to be representative of the total population of patients 
if a study used an obviously representative group or consecutive series of patients (Wells et al., 2014). 
Adequate definition of controls means that a study explicitly stated that the controls had no history 
or symptoms of diabetes, or excluded the diagnosis based on medical examination. Controls were 
considered a representative sample if the study used community controls instead of hospital controls. 
Confounding effects of age and education had to be controlled using matching or statistical 
adjustment. Finally, blind assessment of cognitive performance means that the researcher making the 
assessment was not aware of diabetes status.   
 
RESULTS 
 
Study selection and characteristics 
Figure 1 summarizes the study selection process. The initial search identified 2,040 articles, of which 
120 remained for full-text screening. None of the authors responded to the e-mailed age requests, and 
two authors provided the missing data for effect size calculations. The latter were included in the 
analyses (Kinga & Anett, 2016; Nazaribadie et al., 2013, 2014). One of these authors had two articles 
based on the same study population, reporting results for different neuropsychological methods. 
These two articles were treated as one study (Nazaribadie et al., 2013, 2014). The exclusion process 
resulted in a total of 12 studies eligible for this meta-analysis.  
[INSERT FIGURE 1 HERE] 
Table 1 summarizes the characteristics of the selected studies. Overall, they comprised a total of 2 
122 patients with diabetes and 12 287 healthy controls, with a mean age of 55.5 and 54.8 years, 
respectively. The mean years of education in these groups ranged from 9.9 to 18.3 in patients and 
from 9.9 to 18.9 years in controls. Most of the studies were cross-sectional case-control studies. Only 
half of the studies reported the mean duration of diabetes, which ranged from 6 to 8.5 years. Patients’ 
mean HbA1c (%) values ranged from 6.7 to 10.2 and were reported in eight studies. Three studies 
were conducted in the United States, two in India and the other studies in Germany, the Netherlands, 
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Spain, Romania, Bulgaria, Egypt and Iran. SEMs had to be converted into SDs for effect size 
calculations in one study (Biessels, ter Braak, Erkelens, & Hijman, 2001). 
[INSERT TABLE 1 HERE] 
The results for the assessment of the methodological quality of the studies are presented in 
Supplement 2. Most of the studies confirmed the diagnosis of diabetes either based on a medical 
examination, from medical records, or based on the use of antidiabetic medication. Only three studies 
did not specify whether the diagnosis was objectively confirmed. Eight studies were considered to 
have a representative group of patients. Seven studies explicitly stated that the controls had no history 
or symptoms of diabetes, or excluded the diagnosis of diabetes based on a medical examination. Four 
studies did not state the origin of the control group, but the others used community controls. It should 
be noted that three studies included patients’ relatives as controls. Of these, only one excluded the 
possibility of diabetes in them with a medical examination. As for confounding factors, nine studies 
controlled for the effect of age and seven controlled for the effect of education either by matching or 
statistical adjustment. Only one study explicitly stated that cognitive functions were assessed by a 
researcher who was blind to diabetes status, and one study used computerized assessment.  
 
Meta-analysis of cognitive functions 
Patients performed worse than controls in overall information processing speed (g = -0.68). Figure 
2a displays the results of the meta-analysis. The largest SMD was observed in the Grooved Pegboard 
Test (g = -0.81). Heterogeneity across the effect sizes was statistically significant (Q = 21.9, p = 
0.081, I2 = 36.1 %). There was no evidence of publication bias as the funnel plot appeared to be 
symmetrical (Supplement 3). The subdomain psychomotor speed was assessed in nine studies (g = -
0.68, 95 % CI -0.86 to -0.5, p < 0.001) and motor speed in three studies (g = -0.68, 95 % CI -1.00 to 
-0.36, p < 0.001).  
Attention/concentration was assessed in five studies and overall, patients performed worse 
than controls (g = -0.55; Figure 2b). The largest SMD was observed in the Digit Span Forward (g = 
-0.65). Heterogeneity across the effect sizes was not statistically significant (Q = 3.66, p = 0.599, I2 
= 0.0 %). There was no evidence of asymmetry in the funnel plot (Supplement 3).  
Working memory was assessed in five studies and overall, patients performed worse than 
controls (g = -0.51; Figure 2c). The largest SMD was found in the Paced Auditory Serial Addition 
Test (g = -0.72). Heterogeneity across the effect sizes was statistically significant (Q = 12.97, p = 
0.011, I2 = 69.2 %). There was no evidence of asymmetry in the funnel plot (Supplement 3).  
Patients performed worse than controls in overall executive functions (g = -0.51; Figure 2d). 
The largest SMD was found in part III of the Stroop Test (g = -0.70).  Heterogeneity across the effect 
sizes was statistically significant (Q = 36.74, p = 0.001, I2 = 61.9 %). There was no evidence of 
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significant asymmetry in the funnel plot, but sensitivity analysis was carried out to explore the impact 
of one outlier with large effect size and SE (Supplement 3). After the exclusion of the outlier, the 
effect size remained significant (g = -0.44, 95 % CI -0.61 to -0.27, p < 0.001). The subdomain of 
verbal fluency was assessed in five studies (g = -0.45, 95 % CI -0.83 to -0.08, p = 0.018) and others 
in six studies (g = -0.53, 95 % CI -0.73 to -0.33, p < 0.001).  
Patients performed worse than controls in overall verbal memory (g = -0.39; Figure 2e). The 
largest SMD was found in the immediate recall of the Buschke Free and Cued Selective Reminding 
Test (g = -0.75). Heterogeneity across the effect sizes was statistically significant (Q = 30.2, p = 
0.001, I2 = 66.9 %). There was some evidence of asymmetry in the funnel plot, but no sensitivity 
analysis was performed because there were no significant outliers (Supplement 3). Immediate verbal 
memory was assessed in three studies (g = -0.45, 95 % CI -0.72 to -0.18, p = 0.001) and delayed 
verbal memory in four studies (g = -0.39, 95 % CI -0.44 to -0.34, p < 0.001).  
There was no difference in performance between the patient and control groups in overall 
visual memory (g = -0.15; Figure 2f). The largest SMD was found in the delayed recall of the Rey-
Osterrieth Complex Figure Test (g = -0.63). Heterogeneity across the effect sizes was statistically 
significant (Q = 8.47, p = 0.076, I2 = 52.8 %). There was no evidence of asymmetry in the funnel plot 
(Supplement 3). Immediate visual memory was assessed in two studies (g = -0.15, 95 % CI -0.49 to 
0.19, p = 0.394) and delayed visual memory in three studies (g = -0.16, 95 % CI -0.45 to 0.14, p = 
0.29).  
Language was assessed in three studies and overall, patients performed worse than controls 
(g = -0.26; Figure 2g). The largest SMD was found in the Similarities subtest of the Wechsler Adult 
Intelligence Scale (g = -1.30). Heterogeneity across the effect sizes was statistically significant (Q = 
16.4, p = 0.001, I2 = 81.7 %). There was no evidence of significant asymmetry in the funnel plot, but 
sensitivity analysis was undertaken to explore the impact of one outlier with a large effect and SE 
(Supplement 3). After removal of the outlier, the effect size became non-significant (g = -0.105, 95 
% CI -0.37 to 0.16, p = 0.436).  
Perception/construction was assessed in five studies and overall, patients performed worse 
than controls (g = -0.30; Figure 2h). The largest SMD was found in the copy part of the Rey-Osterrieth 
Complex Figure Test (g = -0.60). Heterogeneity across the effect sizes was not statistically significant 
(Q = 10.69, p = 0.153, I2 = 34.5 %). There was no evidence of significant asymmetry in the funnel 
plot (Supplement 3).  
[INSERT FIGURES 2A-H HERE]. 
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Association between age and effect sizes  
One study had exclusion criteria of age under 60 for patients and controls but did not report the exact 
mean age for the groups (Solanki et al., 2009). This study could not be used in the meta-regression 
analyses. The results from the meta-regression are displayed in Table 2 and scatterplots in Figure 3. 
Age was significantly related to effect size in the domains of information processing speed 
(coefficient (0.056), p = 0.0467), verbal memory (coefficient (-0.063), p = 0.0192), visual memory 
(coefficient (-0.076), p = 0.0106) and language (coefficient (0.105), p = 0.0114). In contrast, age was 
not significantly related to effect size in the domains of attention/concentration (coefficient (-0.015), 
p = 0.638), working memory (coefficient (-0.013), p = 0.759), executive functions (coefficient (-
0.002), p = 0.940) and perception/construction (coefficient (0.025), p = 0.144). 
  
[INSERT TABLE 2 HERE].  
[INSERT FIGURE 3 HERE]. 
 
DISCUSSION 
 
This meta-analysis examined the cognitive functions of middle-aged type 2 diabetes patients 
compared to healthy controls. Patients tended to perform worse than controls in all the cognitive 
functions assessed. The largest standardized mean differences between the groups were found in the 
domains of psychomotor and motor speed, attention/concentration, executive functions, verbal 
fluency, and working memory. Significant differences were also found in immediate and delayed 
verbal memory, language, and perception/construction. The smallest and non-significant differences 
were found in immediate and delayed visual memory. 
Among the main cognitive domains, information processing speed showed the largest effect 
size. Together with executive functions, information processing speed was also the most studied 
cognitive domain. The results are consistent with previous meta-analyses and reviews which mainly 
include older people, indicating that processing speed is one of the most affected cognitive domains 
in patients with type 2 diabetes (Awad et al., 2004; Monette et al., 2014; Palta et al., 2014; Reijmer 
et al., 2010; van den Berg, Kloppenborg, Kessels, Kappelle, & Biessels, 2009). However, the 
magnitude of effect found in this meta-analysis was greater than in previous meta-analyses. Age was 
significantly related to effect size in the information processing speed domain. Patients’ older age 
was related to smaller effect size, which implies that patients performed worse than controls in 
information processing speed domain especially at younger ages. However, only 3% of the variance 
in effect sizes could be explained by age. 
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Similar effect sizes were observed in the subdomains of psychomotor and motor speed, 
although some studies have found that tasks with high motor demands are more affected than tasks 
requiring less motor functions, possibly because of the peripheral neuropathy associated with diabetes 
(Monette et al., 2014; Palta et al., 2014). However, motor speed was assessed in only three studies, 
whereas psychomotor speed was included in nine of the studies reviewed in this meta-analysis. 
Furthermore, the strict categorization of methods into these domains is problematic as 
neuropsychological tests included in the psychomotor speed also involve motor requirements. 
Nonetheless, the results indicate that information processing speed may be one of the most notable 
and one of the earliest cognitive symptoms evident in patients with diabetes.  
The observation of significant effect sizes in executive functions is also consistent with 
previous results (Palta et al., 2014; Reijmer et al., 2010; Sadanand et al., 2015; Vincent & Hall, 2015). 
A slightly larger effect size was found in the subdomain assessing inhibition, mental flexibility, 
planning and abstract reasoning than in the verbal fluency subdomain, although the findings were 
statistically significant in both cases. The magnitudes of the effect sizes in the domains of 
attention/concentration and working memory were quite large compared with the inconsistent and 
smaller effects found in previous research (Kodl & Seaquist, 2008; Monette et al., 2014; Palta et al., 
2014; Sadanand et al., 2015; Vincent & Hall, 2015). However, earlier studies have used widely 
differing categorization systems in these domains, which complicates the interpretation of these 
results. Taking a broader perspective, the significant effects seen in the domains of 
attention/concentration and working memory can be interpreted to be consistent with the result on 
patients’ poorer performance in executive functions. This is because all these three domains are highly 
interrelated and attention and working memory can also be thought to have a role in executive 
functions (Alvarez & Emory, 2006; Diamond, 2013). Patients’ significantly poorer performance in 
executive functions also has great clinical importance since the treatment of diabetes requires many 
skills related to executive functions such as maintaining a healthy diet, exercising, setting and 
achieving treatment goals, and adherence to medication (Diamond, 2013; Tomlin & Sinclair, 2016). 
Significant association between age and effect size was not found in the domains of executive 
functions, working memory and attention/concentration.  
The significant effect sizes seen in verbal memory contradict the findings of Ryan and Geckle 
(2000b), who suggest that memory deficits may not be evident in middle-aged patients but are 
restricted to older patients because of the interaction between normal ageing processes and diabetes-
related metabolic changes. On the other hand, this claim was supported by results from the meta-
regression analyses, in which age was significantly related to effect size in both verbal and visual 
memory domain. Patients’ older age was related to larger effect size and thus, patients performed 
worse than controls in the memory domains especially at older ages. However, as the funnel plot 
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showed some evidence of possible publication bias in the verbal memory and as there was only a 
limited number of studies in memory domains, the results of this meta-analysis should be interpreted 
with caution. In addition, effect sizes in visual memory were not statistically significant. This is 
consistent with studies suggesting that in diabetes, verbal memory is affected to a greater extent than 
visual memory (Awad et al., 2004; Reijmer et al., 2010). However, this view is not consistent with 
the findings of all studies (Monette et al., 2014; Palta et al., 2014), and only three studies had assessed 
the visual memory domain in this meta-analysis. Indeed, more research is needed into the early effects 
of diabetes on memory functions.   
In the language domain, the performance of patients was unexpectedly significantly poorer 
than the performance of controls. Age was significantly related to effect size in the language domain 
with patients performing worse than controls at younger ages. However, these findings must be 
interpreted with caution as there were only three relevant studies in the meta-analysis, and after 
sensitivity analyses the effect size became non-significant. Furthermore, previous studies have shown 
that language abilities are relatively unaffected (Awad et al., 2004; Reijmer et al., 2010). 
Significantly poorer patient performance was also seen in the perception/construction domain. 
This was again an unexpected result since it seems that these functions are not affected in older people 
(Awad et al., 2004; Monette et al., 2014; Reijmer et al., 2010). One possible explanation for this 
conflicting result could be that as visuoconstructional skills have been found to decline with age 
(Harada, Love, & Triebel, 2013), the difference in this domain between patients and controls is greater 
in middle-aged groups than in older people. On the other hand, the methods applied in the 
perception/construction domain also require the use of a number of other cognitive skills, which may 
result in an exaggerated effect size in this domain. For example, the copy part of the Rey-Osterrieth 
Complex Figure Test, where the largest effect size was found, is also related to executive functions 
such as planning and organizational processes (Somerville, Tremont, & Stern, 2000). More research 
is needed into the associations between type 2 diabetes and perceptual and constructional processes. 
Significant association between age and effect size was not found in the perception/construction 
domain. 
Overall, patients’ performance was unexpectedly poorer than the performance of controls in 
all the cognitive functions assessed. However, several factors must be considered when interpreting 
the results. Monette et al. (2014) found some evidence that cross-sectional and case-control studies 
show larger effect sizes than population-based and longitudinal studies. Most of the studies included 
in this meta-analysis were cross-sectional case-control studies, and therefore it is possible that the 
differences in performance between the groups is overestimated. The results of the methodological 
assessment also showed that four studies could not be regarded as having a representative sample of 
patients, and only two studies had used blind assessment of cognitive functions. These results increase 
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the risk for selection and detection bias, respectively. Furthermore, some studies had not controlled 
for the effects of age and education on cognitive performance, which may result in an exaggerated 
estimation of the impact of diabetes on cognitive functions. On the other hand, it is possible that the 
effects of diabetes on cognitive functions are more apparent at a younger age. For example, some 
studies have found stronger associations between diabetes and cognitive functions in younger than in 
older people, possibly because ageing and increased morbidity also impairs cognitive functions in 
aged nondiabetic controls (van Eersel et al., 2013; Winkler et al., 2014). This is consistent with results 
from the meta-regression analyses for information processing speed, in which greater effect sizes 
were associated with younger age. The view is also consistent with findings that type 2 diabetes is 
not associated with an accelerated rate of cognitive decline, but cognitive decrement may have onset 
within a more limited timeframe, possibly in the early phase of the disease (McGrimmon et al., 2012). 
However, there are also conflicting views (Reijmer et al., 2010). 
The strength of this study is that it is the first meta-analysis of cognitive functions specifically 
in middle-aged patients with type 2 diabetes, and it therefore provides a useful basis for future studies 
in this area. In addition, the analyses reviewed comprised a wide range of cognitive abilities, and the 
neuropsychological methods used were classified based on the widely adopted categorization of 
Lezak et al. (2012) and Gurd et al. (2012). This meta-analysis also has several limitations. First, it 
included only a limited number of studies, making generalization difficult. Generalization is also 
hampered by the fact that the studies were conducted in different countries and included people from 
different cultural backgrounds. On the other hand, this can be seen also as a strength of this study, as 
including studies from several countries adds to the external validity of this meta-analysis. Second, 
the classification of neuropsychological methods into specific cognitive domains is problematic since 
most of these domains require several cognitive skills. This also complicates the comparison of the 
results with previous meta-analyses, since different authors have used different classification systems. 
This problem with categorization can also explain some of the unexplained heterogeneity found in 
effect sizes. Third, this meta-analysis did not take into account the impact of comorbidities on 
cognitive performance. This is important since patients with diabetes usually have many 
comorbidities, such as hypertension, dyslipidemia, obesity, and depressive symptoms, which are also 
known to impact cognitive functions (Feinkohl, Price, Strachan, & Frier, 2015; Reijmer et al., 2010; 
van den Berg et al., 2009). Fourth, the results cannot be directly compared to older people (>65), as 
the studies did not report cognitive test scores stratified by both diabetes status and age.  
The results of this study have great importance from a societal point of view. As the 
prevalence of diabetes is rapidly growing and increasing in younger age groups worldwide 
(International Diabetes Federation, 2015), the findings indicate that we can expect to see an increased 
prevalence of cognitive deficits in the working age population, too. Therefore, more research is 
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needed to shed light on cognitive symptoms at the early stages of type 2 diabetes and to confirm these 
results. It is important that future studies in this field more carefully report all their results and 
particularly all the relevant demographic data for both the patient and the control groups, because this 
would eliminate the problems seen in this meta-analysis due to unreported data and also make it easier 
to assess the quality of the studies. Future studies should also use consistent categorizations of 
neuropsychological methods, which would facilitate reliable comparison of the results. In addition, 
future studies should explore the underlying causes and risk factors for early cognitive decrement in 
diabetes. This could improve the detection of the symptoms in the early phase and help prevent later 
cognitive deficits. The early detection of cognitive decrement could also be improved by developing 
effective strategies for screening cognitive decrement in health care systems. Finally, future studies 
should explore the manifestation of cognitive symptoms at different stages of diabetes and at different 
ages. As seen in this study, it is possible that the association between diabetes and cognitive decrement 
can vary according to age in some cognitive domains. Some decrements, such as slowed information 
processing speed, may already be evident at younger ages and in the early phase of the disease, 
whereas others, such as verbal memory decrement, may be more evident later as a result of the 
interaction between normal ageing and diabetes-related metabolic processes. 
In conclusion, the results of this study suggest that type 2 diabetes-related cognitive symptoms 
are not restricted to older age, but can be evident even in middle age in several cognitive functions, 
including information processing speed, executive functions, attention and concentration, working 
memory, and perceptional and constructional skills. In contrast, visual memory seems to be relatively 
unaffected in diabetes patients. Future studies are needed to verify these results and to shed more light 
on early cognitive symptoms associated with diabetes. Health care systems should pay more attention 
to the early screening and treatment of diabetes-related cognitive symptoms, and recognize cognitive 
decrement as a possible complication of diabetes.  
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Figure Legends 
FIGURE 1. Flow chart of article selection process 
FIGURE 2a. Forest plot displaying standardized mean differences and 95 % confidence intervals 
for the information processing speed domain 
FIGURE 2b. Forest plot displaying standardized mean differences and 95 % confidence intervals 
for the attention/concentration domain 
FIGURE 2c. Forest plot displaying standardized mean differences and 95 % confidence intervals 
for the working memory domain 
FIGURE 2d. Forest plot displaying standardized mean differences and 95 % confidence intervals for 
the executive functions domain 
FIGURE 2e. Forest plot displaying standardized mean differences and 95 % confidence intervals 
for the verbal memory domain 
FIGURE 2f. Forest plot displaying standardized mean differences and 95 % confidence intervals for 
the visual memory domain  
FIGURE 2g. Forest plot displaying standardized mean differences and 95 % confidence intervals for 
the language domain 
FIGURE 2h. Forest plot displaying standardized mean differences and 95 % confidence intervals 
for the perception/construction domain 
FIGURE 3. Regression of Hedges’s g on age in the main cognitive domains 
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Figure 3. 
TABLE 1. Characteristics of the studies included in the meta-analysis 
Author, year T2DM C T2DM C T2DM C T2DM C
Aberle et al. 2008 38 421 62.9±0.9 63.0±0.9 9.9±2.3 9.9±2.2 47.4 49.6 1 8.5±5.1 -
Biessels et al. 2001 13 16 57.7±1.8 57.9±1.8 11.2±1.0 11.4±0.7 30.8 50 2 6 (range 2-11) 9.2±0.6
García-Casares et al. 2014 25 25 60.0±4.6 57.8±5.4 18.3±3.6 18.9±4.0 32 44 2 - 6.7±0.8
Kinga et al. 2016 21 34 47.7±5.8 46.6±4.6 11.0±1.0 11.2±1.0 52.4 47.1 2 7.1±2.4 7.4±0.8
Krishna Kumar et al. 2015 50 50 56.4±8.9 58.2±8.2 ≥ HS ≥ HS - - 2 - -
Mehrabian et al. 2012* 37 22 56±8 56±5 14±2 14±2 54 59 2 7±3.5 7.1±0.4
Naseer et al. 2014 20 20 53.3±5.4 - - - 25 - 2 50% > 10 -
Nazaribadie et al. 2013, 2014** 32 30 50.4±6.5 44.9±6.1 12.3±2.4 12.7±2.4 - - 2 - 7.5±2.0
Rawlings et al. 2014 1 779 11 572 58.2±5.7 56.8±5.7 65.1% ≥ HSa  80.9% ≥ HSb 57.2 55.3 1 - 8.0±2.1
Ryan et al. 2000a 50 50 50.8±7.7 50.5±7.4 14.4±3.1 14.0±2.2 70 76 2 8.1±5.9 10.2±2.4
Solanki et al. 2009 50 30 < 60 < 60 - - - - 2 - -
Yau et al. 2009 24 17 57.2±8.1 56.4±6.9 15.3±2.8 16.1±1.8 45.8 52.9 2 7.9±5.6 7.8±1.9
*neuropsychological data were obtained from patients classified as patients with normal cognitive functioning (n = 20)
**studies were combined due to the same study population
a37.9% high school, graduate equivalence degree, or vocational school; 27.2% college, graduate, or professional school 
b42.3% high school, graduate equivalence degree, or vocational school, 38.6% college, graduate, or professional school
T2DM = type 2 diabetes patient group; C = control group; HbA1c = glycated hemoglobin; 1 = prospective, population-based cohort; 2 = cross-sectional, case-
control; HS = high school level
HbA1c 
(%) 
(T2DM)
N Age (mean ± SD) Education years (mean ± SD) Female (%) Duration of 
diabetes   
(mean ± SD)
Study design 
and sampling 
method
TABLE 2. Results from the regression of Hedges’s g on age in the main cognitive domains
Information processing speed Attention/concentration
Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g
Intercept -3,786 1,578 -6,880 -0,693 -2,400 0,017 Intercept 0,303 1,688 -3,006 3,612 0,180 0,858
Age 0,056 0,028 0,001 0,111 1,990 0,047 Age -0,015 0,032 -0,078 0,048 -0,470 0,638
Statistics for Model 1: Statistics for Model 1:
Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero
Q = 3.95, df = 1, p = 0.0467 Q = 0.22, df = 1, p = 0.6381
Goodness of fit:  Test that unexplained variance is zero Goodness of fit:  Test that unexplained variance is zero
Tau² = 0.0231, Tau = 0.1519, I² = 30.42%, Q = 17.25, df = 12, p = 0.1406 Tau² = 0.0000, Tau = 0.0000, I² = 0.00%, Q = 0.94, df = 3, p = 0.8158
Comparison of Model 1 with the null model: Comparison of Model 1 with the null model:
Total between-study variance (intercept only) Total between-study variance (intercept only)
Tau² = 0.0237, Tau = 0.1539, I² = 36.74%, Q = 20.55, df = 13, p = 0.0823 Tau² = 0.0000, Tau = 0.0000, I² = 0.00%, Q = 1.16, df = 4, p = 0.8844
Proportion of total between-study variance explained by Model 1 Proportion of total between-study variance explained by Model 1
R² analog = 0.03 R² analog = 0.00
Working memory Executive functions
Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g
Intercept 0,275 2,234 -4,104 4,654 0,120 0,902 Intercept -0,391 1,402 -3,138 2,356 -0,280 0,780
Age -0,013 0,044 -0,099 0,072 -0,310 0,759 Age -0,002 0,025 -0,050 0,047 -0,080 0,940
Statistics for Model 1: Statistics for Model 1
Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero
Q = 0.09, df = 1, p = 0.7592 Q = 0.01, df = 1, p = 0.9400
Goodness of fit:  Test that unexplained variance is zero Goodness of fit:  Test that unexplained variance is zero
Tau² = 0.0027, Tau = 0.0515, I² = 4.37%, Q = 2.09, df = 2, p = 0.3514 Tau² = 0.0708, Tau = 0.2660, I² = 63.92%, Q = 36.03, df = 13, p = 0.0006
Comparison of Model 1 with the null model: Comparison of Model 1 with the null model
Total between-study variance (intercept only) Total between-study variance (intercept only)
Tau² = 0.0000, Tau = 0.0000, I² = 0.00%, Q = 2.19, df = 3, p = 0.5341 Tau² = 0.0609, Tau = 0.2468, I² = 61.90%, Q = 36.74, df = 14, p = 0.0008
Proportion of total between-study variance explained by Model 1 Proportion of total between-study variance explained by Model 1
R² analog = 0.00 R² analog = 0.00 (computed value is -0.16)
Verbal memory Visual memory
Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g
Intercept 3,197 1,469 0,319 6,076 2,180 0,030 Intercept 3,904 1,591 0,785 7,024 2,450 0,014
Age -0,063 0,027 -0,116 -0,010 -2,340 0,019 Age -0,076 0,030 -0,134 -0,018 -2,560 0,011
Statistics for Model 1: Statistics for Model 1:
Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero
Q = 5.48, df = 1, p = 0.0192 Q = 6.53, df = 1, p = 0.0106
Goodness of fit:  Test that unexplained variance is zero Goodness of fit:  Test that unexplained variance is zero
Tau² = 0.0341, Tau = 0.1846, I² = 39.90%, Q = 14.97, df = 9, p = 0.0916 Tau² = 0.0000, Tau = 0.0000, I² = 0.00%, Q = 1.94, df = 3, p = 0.5855
Comparison of Model 1 with the null model: Comparison of Model 1 with the null model:
Total between-study variance (intercept only) Total between-study variance (intercept only)
Tau² = 0.0661, Tau = 0.2571, I² = 66.89%, Q = 30.20, df = 10, p = 0.0008 Tau² = 0.0775, Tau = 0.2783, I² = 52.79%, Q = 8.47, df = 4, p = 0.0757
Proportion of total between-study variance explained by Model 1 Proportion of total between-study variance explained by Model 1
R² analog = 0.48 R² analog = 1.00
Language Perception/construction
Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g Main results for Model 1, Random effects (MM), Z-Distribution, Hedges's g
Intercept -6,458 2,397 -11,157 -1,760 -2,690 0,007 Intercept -1,684 0,941 -3,528 0,161 -1,790 0,074
Age 0,105 0,042 0,024 0,186 2,530 0,011 Age 0,025 0,017 -0,009 0,059 1,460 0,144
Statistics for Model 1: Statistics for Model 1:
Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero Test of the model: Simultaneous test that all coefficients (excluding intercept) are zero
Q = 6.40, df = 1, p = 0.0114 Q = 2.14, df = 1, p = 0.1438
Goodness of fit:  Test that unexplained variance is zero Goodness of fit:  Test that unexplained variance is zero
Tau² = 0.0550, Tau = 0.2345, I² = 35.37%, Q = 3.09, df = 2, p = 0.2128 Tau² = 0.0118, Tau = 0.1088, I² = 17.58%, Q = 7.28, df = 6, p = 0.2958
Comparison of Model 1 with the null model: Comparison of Model 1 with the null model:
Total between-study variance (intercept only) Total between-study variance (intercept only)
Tau² = 0.3307, Tau = 0.5750, I² = 81.71%, Q = 16.40, df = 3, p = 0.0009 Tau² = 0.0271, Tau = 0.1645, I² = 34.51%, Q = 10.69, df = 7, p = 0.1528
Proportion of total between-study variance explained by Model 1 Proportion of total between-study variance explained by Model 1
R² analog = 0.83 R² analog = 0.56
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